PT-141, also known as bremelanotide, is a prescription medication used to treat hypoactive sexual desire disorder (HSDD), mainly in premenopausal women. It works by activating melanocortin receptors in the brain, which influence sexual desire and arousal rather than blood flow. Unlike drugs such as sildenafil, PT-141 acts on the central nervous system, not the genitals. It is administered as a subcutaneous injection, usually taken about 45 minutes before anticipated sexual activity. The most common side effects include nausea, flushing, headache, and increased blood pressure. PT-141 does not increase libido through hormones like testosterone or estrogen. It is FDA-approved but should be used under medical supervision, especially in people with cardiovascular conditions.
Dosing PT 141:
As a treatment of low sexual desire in women,
bremelanotide is typically administered subcutaneously via self-injection. The most common dosage is 1.75 mg, roughly 45 minutes prior to anticipated sexual activity Patients with HSDD who are prescribed bremelanotide are advised to self-administer it no more than once per day, for a maximum of 8 times per month Those who experience adverse reactions to bremelanotide can reduce the dosage. Research has shown that doses of just 1.25 mg can still produce an effective response.
Studies involving male subjects with or without ED have tested subcutaneous injections of PT-141 ranging from 1 to 10 mg, showing that PT-141 can produce statistically significant results at doses exceeding 1 mg and dose-dependent improvements in erectile function at doses up to 20 mg Research suggests a starting dose of 1 mg as a treatment of erectile dysfunction.